Compare Paycom Software Inc (PAYC) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Paycom Software Inc vs GeneDx Holdings Corp — how do they compare? Paycom Software Inc trades at $232.22 (market cap $10.36B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: Paycom Software Inc is far larger — about 5.1× GeneDx Holdings Corp's market cap, and Paycom Software Inc pays a 0.65% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Paycom Software Inc for 84 Days and GeneDx Holdings Corp for 19 Days on average.
| PAYC | WGS | |
|---|---|---|
Market Cap | $10.36B | $2.02B |
Volume | 666,294 | 734,640 |
Sector | Technology | Health |
52-Week High | $240.52 | $167.51 |
52-Week Low | $113.59 | $34.51 |
Typical Hold Time | 84 Days | 19 Days |
Enterprise Value | $11.15B | $2.05B |
Dividend Yield | 0.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Paycom Software (PAYC) trades at $229.90, up 2.83% today, with a bullish technical signal and strong earnings momentum after beating estimates for three consecutive quarters. The company reported robust Q2 2026 results with 10% revenue growth and raised full-year guidance, supported by a high gross profit margin of 83.67% and solid cash flow generation. Analyst sentiment is mixed but leans positive, with a consensus price target of $207.75.
The outlook remains favorable due to operational leverage and product innovation, though risks include competitive pressures and market volatility. Upside potential hinges on sustained earnings growth and institutional confidence, while any guidance miss or macroeconomic slowdown could pressure the stock.
GeneDx (WGS) trades at $67.73, down 1.17% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $454M in 2026 but faces profitability challenges with a -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth story with expanding genomic testing volumes but carries significant execution risk given negative profitability metrics. Upside potential exists if management can translate revenue growth into sustainable profits, though current cash flow trends and high valuation multiples warrant caution for risk-averse investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Paycom Software Inc
Paycom is a fast-growing provider of payroll and human capital management, or HCM, software primarily targeting clients with 50-10,000 employees in the United States. Paycom was established in 1998 and services about 18,000 clients as of 2021, based on parent company grouping. Alongside its core payroll software, Paycom offers various HCM add-on modules, including time and attendance, talent management, and benefits administration.
Read more on PAYC →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
